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A B S T R A C T
Background: The aim of this study was to investigate the clinical effects of intra-aortic balloon pump
(IABP) in patients who received cardiopulmonary resuscitation (CPR) before procedure.
Methods and results: Between November 2005 and April 2014, 49,542 patients were enrolled in a
prospective cohort study for acute myocardial infarction (AMI) in Korea (KAMIR). CPR was performed in
1700 patients with cardiac arrest. Patients were excluded from the study if they had not undergone a
coronary angiogram, if extracorporeal membrane oxygenation or thrombolysis was performed, and if
mechanical complications presented. The primary end point was 1-month all-cause mortality. A total of
883 patients in the IABP group and 476 in the control group were included. During the 1-month follow-
up, all-cause death occurred in 749 patients (55.1%). The IABP group was predominantly male and had a
higher prevalence of ST-segment elevation MI and a higher risk of coronary lesions including left main
disease and three-vessel disease. Glycoprotein IIb/IIIa inhibitor was administered less in the non-IABP
group. In the total population, the IABP group had worse outcomes in terms of mortality rates after
multivariate analysis [hazard ratio (HR) 1.22, 95% conﬁdence interval (CI) 1.02–1.47, p = 0.034] without
increasing the incidence of recurrent MI, stroke, and major bleeding. After propensity matching with a
* Corresponding author at: Principal Investigator of Korea Acute Myocardial Infarction Registry, Professor, Director of Heart Research Center of Chonnam National
University Hospital, The Heart Center of Chonnam National University Hospital, 671 Jaebongro, Dong Ku, Gwangju 501-757, South Korea. Tel.: +82 62 220 6243;
fax: +82 62 228 7174.
E-mail address: myungho@chollian.net (M.H. Jeong).
1 See Appendix.
http://dx.doi.org/10.1016/j.jjcc.2015.04.007
0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
pair of 452 patients, no signiﬁcant differences were observed in baseline characteristics or clinical
outcomes (HR 1.21, 95% CI 0.93–1.57, p = 0.158).
Conclusion: The use of IABP did not show clinical beneﬁts in patients with AMI complicated by severe
cardiogenic shock after propensity matching analysis.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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The adjunctive use of intra-aortic balloon pump (IABP) has little
evidence of beneﬁt in cardiogenic shock combined with acute
myocardial infarction (AMI). Themost convincing evidence against
the routine use of IABP for treating cardiogenic shock in patients
with AMI is the Intra-aortic Balloon Pump in Cardiogenic Shock
(IABP-SHOCK) II randomized trial [1,2]. In this study, the use of an
IABP did not reduce either 1-month or 1-year mortality without
increasing hemorrhagic complications in patients for whom an
early revascularization strategy was planned. In addition, no
signiﬁcant difference was observed in treated patients with regard
to length of stay in the intensive care unit, renal function during
hospitalization, and general quality of life of survivors during the
1-year follow-up period.
However, a weak point of this study – other than the
development of mechanical complications (26 of 30 patients) –
was the high rate of crossover from the control group to the IABP
group. It is possible that patients with severe shock and an acute
deterioration statuswere not enrolled and if enrolled, crossed over.
In the present study, we investigatedwhether IABP insertion could
be beneﬁcial in patients with AMI complicated severe cardiogenic
shock and planned early revascularization.
Methods
The Korea Acute Myocardial Infarction Registry (KAMIR),
launched in November 2005, is a prospective multi-center data
collection registry reﬂecting real-world treatment practices and
outcomes in Asian patients diagnosed with AMI. The registry
consists of 50 community and teaching hospitals with facilities for
primary percutaneous coronary intervention (PCI) and on-site
cardiac surgery. Eligible patientswere at least 18 years of age at the
time of hospital admission. Patients had a symptomatic history
with or without ST-segment elevation above 2 mm in 2 or more
precordial leads or above 1 mm in 2 or more limb leads, or new
onset of left bundle branch block on the 12-lead electrocardiogram
[(Fig._1)TD$FIG]Fig. 1. Study population diagram. KAMIR, Korea Acute Myoca(ECG) with a concomitant rise of at least one cardiac biomarker of
necrosis. FromNovember 2005 to April 2014, 49,542 patients were
enrolled in the KAMIR. Data were collected by a trained study
coordinator using a standardized case report form and protocol.
The study protocol was approved by the ethics committee at each
participating institution.
Patient characteristics
In the present study, 1700 cardiogenic shock patients underwent
cardiopulmonary resuscitation (CPR) as a result of cardiac arrest
before procedure. Patients were considered to be in cardiogenic
shock if they had a systolic blood pressure of less than 90mmHg
with supportive measures or needed infusion of vasopressors to
maintain a systolic pressure above 90 mmHg, and had clinical signs
of end-organ hypoperfusion such as cold extremities, oligouria, and
mental change. Vasopressors were used in all patients in this study.
Mechanical ventilation was applied in about 80% of the patients.
Patients were excluded from the study based on the following
criteria: if patients did not receive early revascularization strategy
by undergoing a coronary angiogram, if alternate mechanical
circulatory support such as extracorporeal membrane oxygenation
was utilized, if thrombolysis was performed, or if there were
mechanical complications such as ventricular septal defect or acute
severe mitral regurgitation. A total of 1359 patients comprised the
ﬁnal studypopulation. Theyweredivided into twogroups according
to the insertion of IABP (IABP group n = 476, no IABP group n = 883)
(Fig. 1). The decision of the IABP insertion was all left to the
discretion of the operator. The entire study population completed
the 1-month follow-up period with data collection.
Study deﬁnitions
The primary end point of this study was 1-month all-cause
mortality. Safety end points included recurrent MI, stroke, and
major bleeding. Recurrent MI was deﬁned as fulﬁllment of at least
two of the following conditions: recurrent symptoms, newrdial Infarction Registry; IABP, intra-aortic balloon pump.
Table 1






Age (years) 68.211.4 68.512.8 0.725
Male gender 329 (69.1%) 541 (61.3%) 0.004
Height (cm) 159.525.9 160.519.5 0.444




Heart rate (beats/min) 72.235.9 70.537.0 0.419
Hypertension 269 (56.5%) 504 (57.1%) 0.841
Diabetes mellitus 187 (39.3%) 327 (37.0%) 0.414
Dyslipidemia 44 (9.2%) 66 (7.5%) 0.254
Current smoking 154 (32.4%) 301 (34.1%) 0.518
Prior myocardial
infarction
40 (8.4%) 66 (7.5%) 0.542
Prior PCI 30 (6.3%) 49 (5.5%) 0.571
Prior CABG 5 (1.1%) 8 (0.9%) 0.794
Prior stroke 49 (10.3%) 107 (12.1%) 0.314
ST-segment elevation MI 348 (73.1%) 602 (68.2%) 0.059
Infarct-related coronary vessel
Left main 76 (16.0%) 56 (6.3%) <0.001
Left anterior descending artery 233 (48.9%) 419 (47.5%) 0.598
Left circumﬂex artery 57 (12.0%) 109 (12.3%) 0.843
Right coronary artery 110 (23.1%) 299 (33.9%) <0.001
Number of diseased vessel
1 106 (22.3%) 327 (37.0%) <0.001
2 206 (43.3%) 302 (34.2%) 0.001
3 159 (33.4%) 253 (28.7%) 0.069
CABG 52 (10.9%) 54 (6.1%) 0.002
No revascularization 51 (10.7%) 94 (10.6%) 0.969
Glycoprotein IIb/IIIa inhibitor 118 (24.8%) 145 (16.4%) <0.001
Serum creatinine (mg/dL) 1.612.20 1.652.75 0.768
Maximal troponin I (ng/mL) 95.0192.3 106.71009.8 0.763
IABP, intra-aortic balloon pump; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; MI, myocardial infarction.
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cardiac biomarkers to twice the normal baseline value. Major
bleeding was deﬁned as any intracranial bleeding, bleeding events
associated with cause of death, bleeding that required surgery or
transfusion, or any other clinically relevant bleeding as judged by
the investigator.
Loading doses of aspirin and clopidogrel were administered
after patients consented to receive PCI, and a minimum dose of
100 mg aspirin and a 300–600 mg loading dose of clopidogrel and
unfractionated heparin (50–70 U/kg) were administered in order
to maintain an activated clotting time above 250–300 s. The
maintenance dose was 100 mg/day for aspirin and 75 mg/day for
clopidogrel. Coronary artery stenting was performed using the
standard technique. Performance of pre-dilation, direct stenting,
post-adjunctive balloon inﬂation, mode of revascularization
[culprit-only PCI, single or staged-PCI with total revascularization,
or coronary artery bypass surgery (CABG)], insertion of the IABP,
and administration of a glycoprotein IIb/IIIa receptor blocker were
at the discretion of the operator. A post-procedural Thrombolysis
InMyocardial Infarction (TIMI) ﬂow of grade 0 or I was deﬁned as a
failed PCI. Patients for whom medical treatment was planned
without revascularization or those who had undergone a failed PCI
were deﬁned as the ‘‘no revascularization group’’ in this study.
Statistical analysis
All analyses were performed using Statistical Package for the
Social Sciences (SPSS) software version 21.0 (IBM software group,
Chicago, IL, USA). Continuous variables are presented as mean
 standard deviation (SD) and were compared using the Student’s
t test. The Chi-square or Fisher’s exact test was used to determine the
signiﬁcance of differences between categorical variables. A propensi-
ty score analysis was performed to reduce treatment-selection bias
for IABP insertion and potential confounders by using a logistic
regression model (c-statistics = 0.62). Baseline characteristics as
presented in Table 1 were included for this model. A 1:1 matched
analysiswas performed on the basis of the estimated propensity score
for each patient and baseline characteristics were compared after
propensity matching. In the propensity matched population, hazard
ratios between the two groups were compared using Cox propor-
tional hazard models adjusted for important risk co-variables. This
had a signiﬁcant effect (p < 0.2) on the univariate analysis for age,
gender, dyslipidemia, current smoking status, prior stroke,
ST-segment elevation myocardial infarction (STEMI), right coronary
artery culprit, one-vessel disease, three-vessel disease, CABG, no
revascularization, serum creatinine, and maximal troponin I. All
statistical tests were two-tailed, and a p-value less than 0.05 was
considered signiﬁcant. Subgroup analysis was performed in patient
groups that had a tendency to affect the clinical outcomes in the IABP-
SHOCK II trial (age, hypertension, ischemic area, previous infarction).
Results
A total of 1359 patients were included in the ﬁnal analysis. Of
these, 476 patients received IABP and 883 patients did not receive
IABP. Baseline and procedural characteristics of the two groups are
presented in Table 1. The IABP group was predominantly male and
had a higher prevalence of STEMI as well as a higher risk of
coronary lesions such as left main or three-vessel disease.
Glycoprotein IIb/IIIa inhibitor was used less in the non-IABP
group. Serum creatinine and maximal troponin I levels were not
signiﬁcantly different between the two groups. The present study
included patients with severe cardiogenic shock which was
expected to have a prominent effect on IABP. Compared to
IABP-SHOCK II, the present study included a higher risk of coronary
artery disease [STEMI (70.0% vs. 68.8%), the left anterior descendingartery or left main as a culprit (57.7% vs. 52.4%)] and showed worse
outcomes [higher mortality rates (55.1% vs. 40.3%) and increased
incidence of re-infarction or stroke (4.9% vs. 3.4%)]. A total of
452 matched patient pairs were created after propensity score
matching. After matching, no signiﬁcant differences were observed
in the incidence rates of gender, infarct-related artery, multi-vessel
disease, CABG, or glycoprotein IIb/IIIa inhibitor use (Table 2).
Clinical outcomes are presented in Table 3. During the 1-month
follow-up, all-cause death occurred in 749 patients (55.1%). In the
total population, the IABP group exhibitedworse outcomes in terms
of mortality rates after multivariate analysis [HR 1.22, 95%
conﬁdence interval (CI) 1.02–1.47, p = 0.034] with similar rates of
recurrent MI, stroke, and major bleeding across both groups. In
patients without revascularization, mortality rates were similar
between the two groups (84.3% IABP group, 81.9% in non-IABP
group). After propensity matching with multivariate analysis, IABP
implantationdidnot reduce all-causemortalityat1month (HR1.21,
95% CI 0.93–1.57, p = 0.158) without increasing the incidence of
recurrentMI (HR 0.59, 95% CI 0.21–1.65, p = 0.313), stroke (HR 1.19,
95% CI 0.45–3.19, p = 0.727), and major bleeding (HR 1.12, 95% CI
0.53–2.35, p = 0.775) (Fig. 2). No clinical beneﬁt was observed in
IABP patients without revascularization (HR 1.02, 95% CI 0.54–1.94,
p = 0.951) (Fig. 3). As shown in Fig. 4, there was no statistical
interaction between IABP insertion and mortality in the subgroups.
Discussion
In the current guidelines, the use of IABP is recommended for
patients with cardiogenic shock after AMI who have not been
Table 2
Baseline and procedural characteristics of patients matched for propensity score.
Variable IABP (n=452) No IABP (n=452) p-Value
Age (years) 68.511.3 69.411.8 0.199
Male gender 308 (68.1%) 293 (64.8%) 0.291
Height (cm) 159.426.1 161.119.3 0.334
Weight (kg) 63.532.4 64.347.8 0.782
Systolic blood pressure (mmHg) 78.529.8 77.229.7 0.645
Heart rate (beats/min) 70.036.0 71.437.0 0.682
Hypertension 259 (57.3%) 268 (59.3%) 0.544
Diabetes mellitus 179 (39.6%) 187 (41.4%) 0.588
Dyslipidemia 41 (9.1%) 36 (8.0%) 0.551
Current smoking 148 (32.7%) 140 (31.0%) 0.568
Prior myocardial infarction 36 (8.0%) 38 (8.4%) 0.808
Prior PCI 28 (6.2%) 28 (6.2%) 1.000
Prior CABG 5 (1.1%) 7 (1.5%) 0.561
Prior stroke 48 (10.6%) 54 (11.9%) 0.528
ST-segment elevation MI 327 (72.3%) 335 (74.1%) 0.548
Infarct-related coronary vessel
Left main 62 (13.7%) 53 (11.7%) 0.369
Left anterior descending artery 225 (49.8%) 226 (50.0%) 0.947
Left circumﬂex artery 55 (12.2%) 53 (11.7%) 0.838
Right coronary artery 110 (24.3%) 120 (26.5%) 0.445
Number of diseased vessel
1 106 (23.5%) 102 (22.6%) 0.752
2 195 (43.1%) 205 (45.4%) 0.503
3 151 (33.4%) 144 (31.9%) 0.620
CABG 45 (10.0%) 39 (8.6%) 0.492
No revascularization 47 (10.4%) 47 (10.4%) 1.000
Glycoprotein IIb/IIIa inhibitor 106 (23.5%) 104 (23.0%) 0.875
Serum creatinine (mg/dL) 1.592.08 1.622.56 0.898
Maximal troponin I (ng/mL) 106.6216.5 125.71237.6 0.804
IABP, intra-aortic balloon pump; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; MI, myocardial infarction.
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dynamic effects of IABP include improvement of diastolic coronary
ﬂow by inﬂation of the balloon and reduction of afterload by
deﬂation [5]. However, IABP did not improve the diastolic ﬂow
beyond severe coronary artery stenosis [6,7] and micro-vascular
function [8–10]. Although ﬂow augmentation by IABP was
observed after recanalization [6], IABP did not reduce infarct size
[11], did not restore left ventricular ejection fraction, and did not
improve clinical outcomes in randomized trials [12]. Left ventric-
ular unloading by decreasing afterload is another effect of IABP,
and the use of a catecholamine could offset this beneﬁt by
increasing the cardiac afterload and heart rate aswell as decreasing
micro-vascular ﬂow [13]. Therefore, concurrent use of a catechol-
amine could decrease the clinical beneﬁt of IABP.Table 3
Cumulative 1-month clinical outcomes in patients receiving IABP.
IABP No IABP Unadjust
Total (n=1359)
All-cause mortality 285 (59.9%) 464 (52.5%) 1.26
Revascularization 242 (56.9%) 387 (49.0%) 1.29
bNo revascularization 43 (84.3%) 77 (81.9%) 1.08
Recurrent MI 6 (1.3%) 21 (2.4%) 0.59
Stroke 11 (2.3%) 29 (3.3%) 0.82
Major bleeding 21 (4.4%) 36 (4.1%) 1.24
Propensity matched (n=904)
All-cause mortality 268 (59.3%) 247 (54.6%) 1.16
Revascularization 229 (56.5%) 207 (51.1%) 1.19
bNo revascularization 39 (83.0%) 40 (85.1%) 0.97
Recurrent MI 6 (1.3%) 13 (2.9%) 0.50
Stroke 11 (2.4%) 9 (2.0%) 1.33
Major bleeding 19 (4.2%) 17 (3.8%) 1.22
IABP, intra-aortic balloon pump; HR, hazard ratio; CI, conﬁdential interval; MI, myoca
bypass graft; TIMI, thrombolysis in myocardial infarction.
a Adjusted covariates included age, gender, dyslipidemia, current smoking, prior st
one-vessel disease, three-vessel disease, CABG, no revascularization, serum creatin
b Planned medical treatment without revascularization or failed PCI (TIMI ﬂow 0 orIn contrast to existing randomized trial data, IABP showed
different clinical outcomes with regard to thrombolysis and
primary PCI in the registry data. Representative data obtained
from the National Registry ofMyocardial Infarction (NRMI) 2 study
[14] showed that IABP was associated with better outcomes when
used in conjunction with thrombolysis, but worse outcomes when
used with primary PCI [12,14,15]. One possible cause of this
phenomenon is that IABP enhances the efﬁcacy of thrombolysis in
patients with moderate hypotension [16]. Another explanation
could be selection bias of the registry data. In the thrombolysis era,
IABP was more commonly inserted in low-risk patients with a
higher chance of survival [17], and revascularization, which clearly
improved outcomes, was more frequently performed in patients
with IABP [18,19]. After primary PCI, IABP was implanted ined HR (95% CI) p-Value Adjusted HRa (95% CI) p-Value
(1.08–1.46) 0.003 1.22 (1.02–1.47) 0.034
(1.10–1.51) 0.002 1.25 (1.02–1.54) 0.032
(0.74–1.57) 0.693 1.14 (0.67–1.95) 0.629
(0.23–1.47) 0.258 0.69 (0.26–1.84) 0.465
(0.41–1.64) 0.568 0.79 (0.35–1.80) 0.580
(0.72–2.12) 0.435 0.95 (0.49–1.80) 0.863
(0.98–1.38) 0.091 1.21 (0.93–1.57) 0.158
(0.99–1.44) 0.067 1.25 (0.94–1.64) 0.121
(0.63–1.52) 0.907 1.02 (0.54–1.94) 0.951
(0.19–1.32) 0.160 0.59 (0.21–1.65) 0.313
(0.55–3.21) 0.528 1.19 (0.45–3.19) 0.727
(0.63–2.35) 0.554 1.12 (0.53–2.35) 0.775
rdial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery
roke, ST-segment elevation myocardial infarction, right coronary artery culprit,
ine, maximal troponin I.
I).
[(Fig._2)TD$FIG]
Fig. 2.Adjusted cumulative incidence of all causes of death at 1month in propensity
score matched patients. HR, hazard ratio; IABP, intra-aortic balloon pump.
[(Fig._3)TD$FIG]
Fig. 3.Adjusted cumulative incidence of all causes of death at 1month in propensity
score matched patients without revascularization. HR, hazard ratio; IABP, intra-
aortic balloon pump.
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and the IABP group had signiﬁcantly higher risk proﬁles and worse
outcomes compared to those in the control group. The present
study data differ from previous registry data [14,15,20] as a
propensity score matching with multivariate analysis was
performed to reduce potential bias and no signiﬁcant differences
were observed between the two groups.
After the IABP-SHOCK II trial, a handful of studies in the
literature have shown positive results with IABP insertion. A recent
study showed that elective IABP use during high-risk PCI was
associatedwith a 33%mortality reduction at amedian of 51months
[21]. In another previously published study, elective IABP
decreased peri-procedural ischemia or infarction without decreas-
ing mortality rates during the 1-month follow-up period [22]. As
previously mentioned, IABP could be beneﬁcial in terms of left
ventricular unloading as opposed to diastolic ﬂow augmentation.
Contrary to clinical expectations, IABP could be useful in stable
[(Fig._4)TD$FIG]Fig. 4. Subgroup analysis was performed in patient groupswith a tendency to affect the cl
infarction). LAD, left anterior descending artery; RCA, right coronary artery; LCX, left cpatients without the need for catecholamines and with high-risk
coronary lesions and myocardial dysfunction. However, these
beneﬁcial effects would not be immediately apparent and would
be shown during a longer-term follow-up period.
Asmentioned above, IABP is still regarded as a reasonable option
inpatientswith cardiogenic shock afterAMIdespite negative results
from the IABP-SHOCK II study. However, the classiﬁcation of the
recommendation was downgraded compared with the previous
guideline. According to the 2004 American College of Cardiology/
American Heart Association (ACC/AHA) STEMI guideline, IABP was
class I indication and should be used in cardiogenic shock patients
[23]. But, in 2013 ACC/AHA guideline, IABP was class IIa indication
and can be used in this patient group [4]. The European guideline
stated that IABP may be considered (IIb) [3]. The German-Austrian
guideline stated that IABP had no evidence-based recommendation
possible in patients with PCI [24]. IABP might continue to be used
in cardiogenic shock unless powerful alternative devices areinical outcome of the IABP-SHOCK II trial (age, hypertension, ischemic area, previous
ircumﬂex artery; MI, myocardial infarction; IABP, intra-aortic balloon pump.
H.K. Kim et al. / Journal of Cardiology 67 (2016) 57–6362introduced. But, it is used based on pathophysiologic mechanism
and anecdotal experience, not by evidence of beneﬁt.
There were several limitations to this study. First, the non-
randomized nature of the registry data could result in selection
bias. Although most confounders were included in the multivari-
able analysis and propensity score matching, it is possible that
some potential confounders may have been excluded. Further-
more, adjustment for the propensity score did result in a reduction
in population size and a subsequent loss of statistical power.
Second, this study lacked detailed data regarding time for return of
spontaneous circulation, initial rhythm at the time of CPR,
vasopressor name and requirements, lactic acid levels which
could show the shock status of patients, and left ventricular
function immediately after PCI. It is therefore difﬁcult to evaluate
the daily change in patient condition. Systolic blood pressure and
heart rate at the time of admission were included in our analysis.
These parameters were not signiﬁcantly different. Third, there was
no core laboratory center in our registry. Study entry institutions
used different laboratory assays in this study. Fourth, the timing
and duration of IABP placement (either before or after PCI) were
not included in this registry dataset. This could affect clinical
outcomes although previous studies have shown conﬂicting
results in this regard [25,26]. Similar mortality rates were shown
in the IABP-SHOCK II trial regardless of IABP timing.
Conclusions
IABP is used in subjects with especially high risk of death in
real-world practice. The use of IABP did not show clinical beneﬁt in
patients with AMI complicating acute deterioration cardiogenic
shock after propensity score matching analysis. Further studies
which include detailed information of vital status, and patients
who received early conservative strategies are needed to clarify the
effect of IABP in this category of patients’ group.
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